In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.
This cohort study evaluates the survival outcomes of currently smoking patients with cancer who entered into a smoking cessation treatment program based on the time…
Mrs A., at the age of 58 years, was referred by her oncologist to the early palliative care (EPC) outpatient ambulatory clinic of our cancer…
The OncoAlert Newsletter is now out for June 23-29, 2023
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
During the 66th ASH Annual Meeting and Exposition, Mehta P. presented results from a post-hoc analysis of the UK NCRI AML19 trial evaluating the efficacy…
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, comments on a pilot study within a larger Phase Ib study (NCT02513186) of isatuximab,…
Abstract. Cancer is a complex disease in which several molecular and cellular pathways converge to foster the tumoral phenotype. Notably, in the latest iteration of…
